Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples

被引:4
作者
Kaya, Aslihan Gurun [1 ]
Ciledag, Aydin [1 ]
Erol, Serhat [1 ]
Oz, Mirac [1 ]
Mulazimoglu, Deniz Dogan [1 ]
Isik, Ozlem [1 ]
Ozakinci, Hilal [2 ]
Ciftci, Fatma [1 ]
Sen, Elif [1 ]
Ceyhan, Koray [2 ]
Kaya, Akin [1 ]
Karnak, Demet [1 ]
Celik, Gokhan [1 ]
Ismail, Savas [1 ]
机构
[1] Ankara Univ, Dept Chest Dis, Fac Med, TR-06100 Ankara, Turkey
[2] Ankara Univ, Dept Pathol, Fac Med, Ankara, Turkey
关键词
Non-small cell lung carcinoma; lung cancer biomarker; molecular analysis; endobronchial ultrasound; targeted therapy; GROWTH-FACTOR RECEPTOR; TRANSBRONCHIAL NEEDLE ASPIRATION; MOLECULAR TESTING GUIDELINE; ENDOBRONCHIAL ULTRASOUND; INTERNATIONAL-ASSOCIATION; MUTATION ANALYSIS; DIAGNOSIS; COLLEGE; EGFR; SPECIMENS;
D O I
10.1177/00369330221078995
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject. Aim The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers. Methods We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020. Results A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing. Conclusion EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.
引用
收藏
页码:18 / 27
页数:10
相关论文
共 48 条
[1]   The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities [J].
Aisner, Dara L. ;
Sams, Sharon B. .
DIAGNOSTIC CYTOPATHOLOGY, 2012, 40 (06) :511-524
[2]   The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer [J].
Bilgin, Burak ;
Hizal, Mutlu ;
Yucel, Sebnem ;
Sendur, Mehmet Ali Nahit ;
Akyurek, Nalan ;
Akinci, Muhammed Bulent ;
Yilmaz, Ulku ;
Yalcin, Bulent .
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (02) :118-125
[3]   Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors [J].
Chen, Justin A. ;
Riess, Jonathan W. .
JOURNAL OF THORACIC DISEASE, 2020, 12 (05) :2859-2876
[4]   Adequacy of EBUS-TBNA specimen for mutation analysis of lung cancer [J].
Cicek, Tugba ;
Ozturk, Ayperi ;
Yilmaz, Aydin ;
Aktas, Zafer ;
Demirag, Funda ;
Akyurek, Nalan .
CLINICAL RESPIRATORY JOURNAL, 2019, 13 (02) :92-97
[5]   Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California [J].
DeRouen, Mindy C. ;
Hu, Lauren ;
McKinley, Meg ;
Gali, Kathleen ;
Patel, Manali ;
Clarke, Christina ;
Wakelee, Heather ;
Haile, Robert ;
Gomez, Scarlett Lin ;
Cheng, Iona .
PLOS ONE, 2018, 13 (05)
[6]   Epidemiology of lung cancer in Northern Greece: An 18-year hospital-based cohort study focused on the differences between smokers and non-smokers [J].
Domvri, Kalliopi ;
Porpodis, Konstantinos ;
Zisi, Panagiota ;
Apostolopoulos, Apostolos ;
Cheva, Angeliki ;
Papamitsou, Theodora ;
Papakosta, Despoina ;
Kontakiotis, Theodoros .
TOBACCO INDUCED DISEASES, 2020, 18
[7]   Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment [J].
Duma, Narjust ;
Santana-Davila, Rafael ;
Molina, Julian R. .
MAYO CLINIC PROCEEDINGS, 2019, 94 (08) :1623-1640
[8]   Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians [J].
Ernst, A ;
Silvestri, GA ;
Johnstone, D .
CHEST, 2003, 123 (05) :1693-1717
[9]   Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Aisner, Dara L. ;
Akerley, Wallace ;
Bauman, Jessica R. ;
Bharat, Ankit ;
Bruno, Debora S. ;
Chang, Joe Y. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Dilling, Thomas J. ;
Dowell, Jonathan ;
Gettinger, Scott ;
Gubens, Matthew A. ;
Hegde, Aparna ;
Hennon, Mark ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Leal, Ticiana A. ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Lovly, Christine M. ;
Martins, Renato G. ;
Massarelli, Erminia ;
Morgensztern, Daniel ;
Ng, Thomas ;
Otterson, Gregory A. ;
Patel, Sandip P. ;
Riely, Gregory J. ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Singh, Aditi P. ;
Stevenson, James ;
Tam, Alda ;
Yanagawa, Jane ;
Yang, Stephen C. ;
Gregory, Kristina M. ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03) :254-266
[10]   NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Akerley, Wallace ;
Bazhenova, Lyudmila A. ;
Borghaei, Hossein ;
Camidge, David Ross ;
Cheney, Richard T. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Dilling, Thomas J. ;
Dobelbower, M. Chris ;
Govindan, Ramaswamy ;
Hennon, Mark ;
Horn, Leora ;
Jahan, Thierry M. ;
Komaki, Ritsuko ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Lilenbaum, Rogerio ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Martins, Renato ;
Otterson, Gregory A. ;
Patel, Jyoti D. ;
Pisters, Katherine M. ;
Reckamp, Karen ;
Riely, Gregory J. ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Sharma, Neelesh ;
Stevenson, James ;
Swanson, Scott J. ;
Tauer, Kurt ;
Yang, Stephen C. ;
Gregory, Kristina ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03) :255-264